Actemra (tocilizumab), an IL-6 receptor antagonist used to manage cytokine storm in COVID-19, may modulate tumor-promoting inflammatory pathways, but its impact on CRC-specific targets like CD147 is poorly understood (10–12). The gene discussed is BSG; the disease is colorectal carcinoma.